Pharmaceutical Norwegian clinical-stage radiopharma company Oncoinvent, which is developing Radspherin, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announced the appointment of Dr Zuzana Jiráková Trnková as chief medical officer (CMO), effective November 4, 2026. 28 October 2026